General Toxicity Notes
May cause excessive sedation in ESRD.
Half-Life (Normalesrd) Hours
1.4-2.1/2.1-4.8
Plasma Protein Binding %
50
Volume Of Distribution L/Kg
0.46-0.82
Dose For Normal Renal Function
8.0 mg qid
Adjustment For Renal Failure Method
I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
qid [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
bid-tid [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
bid-q24h [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR 10-50, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Brogden RN, McTavish D. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991; 41: 927-40. [PMID: 1715267] / Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med. 2002; 113 Suppl 9A: 38S-46S. [PMID: 12517581]
Toxicity Notes
Combination of acrivastine and pseudoephedrine. The manufacturer does not recommend the use of acrivastine/pseudoephedrine fixed combination in patients with renal impairment. Approximately 20% of the dose is removed by hemodialysis. Dose adjustment calculated from half-life ratios.